ClinicalTrials.gg
CompletedNCT07133191Updated Jul 14, 2026

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

A Phase 1 interventional study of Selatogrel and Matching placebo in Healthy Volunteers, sponsored by Viatris Innovation GmbH. Completed at 1 site in United States. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of selatogrel following a single dose in healthy Japanese and Caucasian participants. Pharmacokinetics is the study of the absorption and breakdown of the study drug in the body. Pharmacodynamics is the study of the effect of the study drug on the body. There will be 2 groups in the study: 16 Japanese participants in one group and 16 Caucasian participants in the other group.

The duration of participation in this study is approximately 70 days from screening to the end of follow-up. A screening visit is required within 28 days prior to the start of the study to determine whether the volunteer qualifies and is willing to participate in this research study. This study requires in-patient stay in the research clinic of 3 or 4 days (2 or 3 nights), an end-of-trial (EOT) examination at least 36 hours after study drug administration, and a post-trial safety follow-up telephone call or site visit 30-40 days after the EOT examination.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Signed and dated form in a language understandable to the participants prior to any trial-mandated procedure.
  • Participant must be of either Caucasian (with European, North African, Middle Eastern origins) or Japanese ethnicity.
  • (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at Screening.
  • Systolic blood pressure 90-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on the dominant arm, after 5 min in the supine position at Screening.
  • 12-lead (ECG) without abnormalities, measured after 5 min in the supine position at Screening.
  • Clinical chemistry test results not deviating from the normal range to a clinically relevant extent at Screening.
  • Hematology and coagulation test results not deviating from the normal range to a clinically relevant extent at Screening and on admission.
  • Negative results from urine drug screen and alcohol breath test at Screening and on admission.
  • Ability to communicate well with the investigator, in a language understandable to the participant, and to understand and comply with the requirements of the trial.
  • For participants of : Negative results from serum pregnancy test at Screening and urine pregnancy test on admission. They must consistently and correctly use (from Screening, during the entire trial, and for at least 30 days after trial intervention injection) an acceptable method of , be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must be initiated at least 1 month before trial intervention administration.

Main Exclusion Criteria:

  • Previous exposure to selatogrel.
  • Pregnant or lactating participant.
  • Known to P2Y12 receptor antagonists or to used in any of the formulations.
  • Family or personal history of prolonged bleeding (e.g., after surgical intervention) or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial vascular diseases, stroke, , reasonable suspicion of vascular malformations, peptic ulcers.
  • count \< 120 × 109 L-1 at Screening or on admission.
  • Any known platelet disorder (e.g., Glanzmann thrombo-asthenia, von Willebrand disease, platelet release defect).
  • Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs, P2Y12 receptor antagonists, or any medication with blood-thinning activity (i.e., injectable or oral anticoagulants) within 3 weeks prior to trial intervention administration.
  • Treatment with another small-molecule drug within 3 months or 5 × half-life (t1/2, whichever is longer) or with an investigational antibody treatment within 6 months prior to Screening, or participation in more than 4 investigational drug trials within 1 year prior to Screening.
  • Excessive caffeine consumption from trial drug administration to EOT, defined as ≥ 800 mg per day at Screening.
  • Nicotine use within 3 months prior Screening and inability to refrain from nicotine intake from Screening until EOT.
  • History or clinical evidence of alcoholism or drug abuse within 3 years prior to Screening.
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) with the exception of contraceptives for participants of childbearing potential within 2 weeks or 5 × t1/2 (whichever is longer) prior to study drug administration.
  • History of major medical or surgical disorders, which in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed).
  • History of asthma.
  • Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • Legal incapacity or limited legal capacity or vulnerability (e.g., kept in detention) at Screening.
  • Known hypersensitivity or allergy to natural rubber latex.
  • Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the trial.
  • Participant is the investigator or any delegate, research assistant, pharmacist, trial coordinator, other staff from trial site or the sponsor directly involved in the conduct of the trial or their relatives.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Selatogrel

    Study treatment is administered in the morning as a subcutaneous single dose.

    Combination Product: Selatogrel

  • Placebo comparator
    Placebo

    Study treatment is administered in the morning as a subcutaneous single dose.

    Combination Product: Matching placebo

Interventions

  • Combination productSelatogrel

    Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. A single dose of 16 mg selatogrel will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.

    Also known as: ACT-246475

  • Combination productMatching placebo

    A single dose of placebo will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t)

    The plasma selatogrel PK parameters will be derived by non compartmental analysis of the concentration-time profiles

    Time frame: Up to 36 hours post-dose

  2. Area under the plasma concentration-time curve from zero to infinity (AUC0-infinity)

    The plasma selatogrel PK parameters will be derived by non compartmental analysis of the concentration-time profiles

    Time frame: Up to 36 hours post-dose

  3. Maximum plasma concentration (Cmax)

    The measured individual plasma concentrations of selatogrel will be used to directly obtain Cmax

    Time frame: Up to 36 hours post-dose

  4. Time to reach maximum plasma concentration (tmax)

    The measured individual plasma concentrations of selatogrel will be used to directly obtain tmax

    Time frame: Up to 36 hours post-dose

  5. Terminal half-life (t1/2)

    The plasma selatogrel PK parameters will be derived by non compartmental analysis of the concentration-time profiles

    Time frame: Up to 36 hours post-dose

07

Study locations

1 site
  • CenExel ACT (Anaheim Clinical Trials)
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Nov 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 20, 2025
StartActual
Oct 7, 2025
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 6, 2025
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07133191
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Oct 7, 2025
Primary completion
Nov 5, 2025
Completion
Nov 6, 2025
Last update
Jul 14, 2026

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion